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Accepted 28 August 2009AbstractObjectives: The aim of this study was to compare the efficacy of vaginal misoprostol with vaginal dinoprostone for term labor induction.
Material and Methods: It was a randomized controlled trial done in the Obstetrics Department, Shifa Community Health Centre, Shifa Inter-
national Hospital (Teaching Hospital of Shifa College of Medicine, Islamabad). All pregnant women at term pregnancy coming for induction of
labor were enrolled. 246 women fulfilled the inclusion criteria. Out of them 208 women consented to be part of the study. These women were
then randomized to receive either Treatment A (vaginal misoprostol) or Treatment B (vaginal dinoprostone). Data were completed for 200
women. These included induction labor and induction-delivery interval, fetal and maternal complications, and baby apgar score.
Results: Out of 200 women in the study, 100 were in Group A and 100 in Group B. Labor commenced in a mean of 6.67 hours (3.63) in Group
A whereas it took a mean of 8.41 hours (5.13) in Group B (p ¼ 0.00). Actual induction to delivery (of the baby) interval was a mean of
11.68 hours (4.55) for misoprostol and 15.37 hours (5.30) for dinoprostone group (p ¼ 0.00). There were no cases of uterine rupture in both
groups; however, there were 10 cases of uterine hyperstimulation in Group A and 4 in Group B (p ¼ 0.09).
Conclusions: It is time to re-evaluate the role of misoprostol for term labor induction. It is an efficacious and cost-effective alternative to the
presently licensed treatment.
Copyright  2011, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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Labor induction involves the stimulation of uterine con-
tractions to produce delivery before the onset of spontaneous
labor. This procedure has been commonly used since the
synthesis of oxytocin in the 1950s and labor is currently
induced in about 13% of live births in the United States [1].
Most labor inductions are for post-date pregnancy, which
occurs in about 10% of live births [1]. Prostaglandin E2
(dinoprostone; Prepidil, Cervidil), administered intra-vagi-
nally or intra-cervically, is the pharmacologic agent most* Corresponding author. Obstetrics and Gynecology, Shifa College of
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doi:10.1016/j.tjog.2009.08.001widely used for ripening the cervix [2e4]. Its use is licensed
by the United States Food and Drug Administration for
cervical ripening. Misoprostol (Cytotec, Orthotec) has been
extensively investigated in the past few years for use in
cervical ripening and labor induction [5]. Marketed as a gastric
cytoprotective agent, the drug is also an effective, safe, and
inexpensive agent for cervical ripening and labor induction,
although it is not food and drug administration United states
(FDA)-labeled for that purpose [6e15]. The aim of this study
was to compare the efficacy of vaginal misoprostol with
vaginal dinoprostone for term labor induction and to assess
whether it has the potential to replace the existing drug.
Material and methods
It was a randomized controlled trial. The sample size was
calculated by using WHO software. Level of significancecs & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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size was separately estimated for each outcome including
induction-delivery interval in hours (11.9 0.6 hours for
misoprostol and 15.6 0.7 hours for dinoprostone), need for
oxytocin (65.8% in misoprostol and 80.7% in dinoprostone
group, p< 0.05), and fetal effects (1 minute apgar score< 7,
12.5% in misoprostol and 6% in dinoprostone group) [26]. The
sample size calculated was 85 in each group. It was increased
to 104 in each group to cover contingencies such as refusals
during the trial, missing or incomplete data.
Approval of the study was taken from the 22-member ethical
review board of the Shifa International Hospital, Islamabad,
Pakistan, comprising religious scholars, bio-ethics and research
specialists, doctors, and the dean of the institution. All pregnant
women presenting in Shifa Foundation Community Health
Centre (Shifa International Hospital, Pakistan) outpatient who
were planned for induction of labor had their evaluation
regarding inclusion criteria. Women with a parity of four or less
and a gestation of 38 weeks or more with a single fetus in
cephalic presentation and a Bishop score of 6 or less were
enrolled, whereas women with previous cesarean delivery,
transverse lie, active herpes, placenta previa & severe intra
uterine growth restriction (IUGR) in present pregnancy,
multiple pregnancy, breech presentation, bad obstetrical
history/intrauterine growth restriction (less than 10th percen-
tile), pre-eclampsia, poly- or oligohydramnios, and Bishop
score 7 ormorewere excluded. All eligiblewomen presenting at
Shifa foundation antenatal outpatient fulfilling inclusion
criteria and who had consented to be part of the study were
enrolled. After evaluation, 246 women were found eligible for
inclusion in the study. Out of these 208 women agreed to be part
of the trial. Eight cases did not complete the trial protocol
(refused drug administration as was required) and were dropped
out of the analysis. Women included were explained about this
clinical trial and their written informed consent was taken.
Randomization was done by using computer software. Women
were randomized to receive either Treatment A (vaginal
misoprostol) or Treatment B (vaginal dinoprostone). Random-
ization was done in blocks of four to ensure equal number of
women in each group. One hundred and four women were
allocated to Treatment A and 104 women to Treatment B.
According to generated randomization list 208 envelopes were
prepared and the name of allocated treatment was placed in each
envelope. These envelopes were then sealed. All the envelopes
were serially numbered from 1 to 208 on the outside. When
a woman was admitted for induction in labor ward, the first
envelope was opened by the attending nurse under close
supervision of the principal investigator. Principal investigator
was there to ensure that the allocated treatment plan was
adhered to. Once the treatment was allocated to a woman it was
strictly adhered to. Neither the nurse nor the principal investi-
gator could change the allocated treatment. The study was
double blinded (neither the patient nor the outcome assessor
knew about the type of allocation). Only the attending nurse
and the principal investigator knew about treatment allocation.
The outcome assessor was a separate physician who had no
knowledge about the type of intervention given. Afterrandomization, either 50 mg misoprostol or 3 mg dinoprostone
was inserted in the posterior vaginal fornix of the patient by the
labor ward nurse. The Bishop score at induction and the time of
induction were clearly documented in patient’s notes. The
doctor in charge of the patient then recorded the progress of
labor on the partogram. A 30-minute fetal cardiotocography
(CTG) was performed 1 hour after insertion. Afterwards inter-
mittent fetal heart auscultation was done. If the patient started
complaining of labor pains, uterine contractions were recorded
and examination was repeated to reassess Bishop score. In the
absence of labor pains, a repeat Bishop score was done 6 hours
after the first drug administration. Re-insertion of second tablet,
if Bishop score was 6 or less, was preceded by a 20-minute pre-
insertion CTG and then a 20-minute post-insertion CTG (1 hour
after insertion of the second tablet). A maximum of three
insertions were attempted in 6 hours with this protocol to induce
labor. If the Bishop score was still poor after three tablets it was
recorded as drug failure. If Bishop score improved up to 7 or
more, artificial rupture of membranes was done and labor was
followed as per regular protocol. Outcome in terms of mode of
delivery, baby apgar scores, and possible complications (uterine
tachysystole, uterine hyperstimulation, uterine rupture, post-
partum hemorrhage, and fetal distress or fetal death) was
recorded for each case.
Primary outcome measure was efficacy of misoprostol in
comparison with dinoprostone for inducing labor. Whereas
secondary outcome measures included feto-maternal compli-
cations, baby apgar scores, and possible complications like
uterine tachysystole, uterine hyperstimulation, uterine rupture,
post-partum hemorrhage, and fetal distress or fetal death, and
cesarean rates. Five uterine contractions for 10 minutes per-
sisting for 20 minutes was labeled as uterine tachysystole,
whereas cutoff of a contraction persisting for 120 minutes was
used to label the case as uterine hypersystole/hypertonus. CTG
was assessed by the on duty trained labor ward doctor and
abnormal CTGs were informed to the specialist obstetrician
who re-evaluated them. Hence fetal heart rate changes such as
late decelerations, persistent variable decelerations, persistent
brady- or tachycardia, and decreased baseline variability were
indicators used to label the CTG as abnormal [18].
Data entry and analysis were done in SPSS version 10
(SPSS Inc., Chicago, IL, USA). Intention to treat analysis was
done for comparison of quantitative variables like induction
labor and delivery interval by using independent sample t test.
Pearson c2 test was applied for comparison of categorical
variables (fetal and maternal complications). Level of statis-
tical significance was p< 0.05.
Results
A total of 208 women were recruited. Complete data were
available for 200 women, 100 in Group A and 100 in Group B.
The two groups were matched for confounding factors such as
age, gravidity, and Bishop score. The mean age of the women in
the study group was 26.22 years. There was no statistical differ-
ence (p ¼ 1.00) between the gestational age of women in both
groups (Table 1) and the most common reason for induction of
Table 1
Descriptive statistics
n Mean  standard deviation
Age (yr) 200 26.22  3.40
Gravidity 200 2.20  1.24
Gestational age 200 40.11  1.37
Bishop score 200 3.12  1.28
Table 3
Results of secondary outcome measures
Misoprostol Dinoprostone p
Use of oxytocin 36 (43.4) 47 (56.6) 0.114
Uterine rupture 0 0
Uterine
hyperstimulation
10 (71.4) 4 (28.6) 0.096
Post-partum
hemorrhage
9 (36) 16 (64) 0.134
Abnormal CTG
(% age within fetal
complication)
14 (50) 14 (50)
Meconium
(% age within fetal
complication)
0 7 (100)
Apgar score #6 8 (8) 15 (15) 0.36
>6 92 (92) 85 (85)
Data are presented as n or n (%).
CTG¼ cardiotocography.
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score was poor 3.1 95% confidence interval for misoprostol
group than for dinoprostone group 3.1 95% confidence interval
though not statistically significant (p ¼ 0.6).
Primary outcome measures including drug dose adminis-
tered, induction labor interval, and induction-delivery interval
for both the groups are shown in Table 2. When the two groups
were compared regarding mode of delivery, there were 84
(54.2%) normal deliveries in the misoprostol group and 71
(45.8%) in the dinoprostone group. Instrumental deliveries
were required in 39.4% women in the misoprostol group and
60.6% women in the dinoprostone group. It was noted that
25% women induced with misoprostol and 75% women
induced with dinoprostone required cesarean section. But
these differences did not reach statistical significance
(p¼ 0.06). The results of secondary outcome measures like
oxytocin use, uterine rupture, uterine hyperstimulation, post-
partum hemorrhage, abnormal CTGs, meconium staining, and
apgar scoring are given in Table 3.
Discussion
The main outcome was induction labor and induction-
delivery interval. A statistically significant decrease in the
induction to onset of labor interval was seen in the misoprostol
group. The mean duration was 6.67 in misoprostol group and
8.40 in dinoprostone group ( p¼ 0.000) with the additional
benefit of a lesser dose of misoprostol [mean of 1.7 doses were
required as compared to dinoprostone, where a mean of 2.1
doses used (p¼ 0.003)].
These results were in concordance with Neiger and Greaves
who reported fewer doses and a shorter induction-delivery
interval with misoprostol (p¼ 0.007) [7] and the same opinion
was expressed by Chang et al in their study [8]. Danielian and
Porter were of the opinion that more women delivered after
only one dose (77% vs. 49%) of 50 mg vaginal misoprostol
[11] and this was also concluded by Hassan [12].Table 2
Results of primary outcome measures
Mode of induction n M
Number of doses Misoprostol 100 1
Dinoprostone 100 2
Induction labor interval Misoprostol 100 6
Dinoprostone 100 8
Induction-delivery interval Misoprostol 97 11
Dinoprostone 91 15The other main outcomewas the induction-delivery interval.
In our study, the mean induction to delivery interval was
3.68 hours (p¼ 0.000) shorter in themisoprostol group. Khoury
also reported a shorter interval from induction to vaginal
delivery in nulliparous women receiving misoprostol (21.3
hours vs. 27.2 hours) [15]. Chang and Chen concluded
a significantly shorter induction-delivery interval (approx.
177 minutes) in their misoprostol group [8]. While in their
review of trials of misoprostol used for term labor induction,
Hofmeyr and Gulmezoglu found misoprostol to be associated
with lower failure rates for achieving vaginal delivery compared
to other prostaglandins [16].
In this study, vaginal deliveries were more in the misoprostol
group as compared to dinoprostone. While out of 12 cesarean
sections performed, 3 cases were from misoprostol and 9 from
dinoprostone group. Ramos and Kaunitz in their review also
felt that misoprostol was associated with a significantly lower
overall rate of cesarean section (odds ratio 0.67) and a higher
incidence of vaginal delivery (odds ratio 2.64) within 24 hours
of insertion [13]. Whereas in a comparison between use of
misoprostol in women at term (36 weeks of gestation) with
control, misoprostol had a significantly increased rate of
vaginal delivery compared to other methods [14]. On the
contrary, Van Gemund and Scherjon found a longer median
induction-delivery interval in misoprostol group compared with
dinoprostone; however, the caesarean section rate was lower in
the misoprostol group: 16.1% versus 21% [17].ean  standard deviation p 95% confidence interval
Lower Upper
.77  0.84 0.003 0.565 0.114
.11  0.78 0.003 0.565 0.114
.67  3.63 0.006 2.971 0.490
.40  5.13 0.007 2.972 0.489
.69  4.56 0.000 5.105 2.265
.37  5.30 0.000 5.111 2.258
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dinoprostone group as compared to misoprostol. We used the
Cochrane Database [18] definitions while evaluating uterine
hyperstimulation, tachysystole, and CTG abnormalities.
Abnormal CTGs were read by specialist obstetrician on call in
labor ward, and abnormalities in terms of fetal heart rate
changes such as late decelerations, persistent variable deceler-
ations, persistent brady or tachycardia, and decreased baseline
variability were indicators used to label the CTG as abnormal.
We found no case of uterine hyperstimulation or hyper-
tonus but tachysystole occurred in 10 cases of misoprostol
group and 4 patients of dinoprostone group. Our study was not
powered to determine the statistical significance of this factor.
An equal number of abnormal CTGs (14%) in both study
groups was seen; however, meconium staining of liquor was
present in seven cases of dinoprostone group and none of the
misoprostol group.
The 1-minute apgar was less than 6 in 8% of misoprostol and
15% of dinoprostone group. The Cochrane Pregnancy and
Childbirth Group trials register, comparing placebo to miso-
prostol concluded that misoprostol was associated with
a reduced, failure to achieve vaginal deliverywithin 24 hours and
there were no significant differences in the incidence of tachy-
systole, hypersystole, and hyperstimulation. No maternal and
neonatal adverse effects were noted with misoprostol use [19].
International studies have found the incidence of uterine
contraction abnormalities (tachysystole and hyperstimulation)
and the incidence of abnormal CTG recordings similar for both
misoprostol and dinoprostone [9]. Montvale, NJ reported less
neonatal intensive care admissions (8.7%) in misoprostol
versus (10.8%) in dinoprostone group [20]. No fetotoxic,
teratogenic, or carcinogenic effects have been observed in
animal studies, and no untoward direct effects on neonates have
been noted so far in any of the clinical trials [6,21e25]. Khouri
and Zhou were unable to find significant differences between
misoprostol and dinoprostone groups in adverse maternal, fetal,
or neonatal effects. And Danielian and Porter also concluded
that misoprostol use was not related to any adverse neonatal
outcomes. Results of Van Gemund and Scherjon also validated
the fact that ‘adverse neonatal outcome’ was similar in both
groups and fewer neonates were admitted to neonatal intensive
care unit in the misoprostol group compared with dinoprostone
19% versus 26%. Other international data [24e28] also were
consistent with the fact that misoprostol was more effective
than dinoprostone without any serious increase in untoward
effects. Since we had used vaginal route for administration of
both the drugs, commonly encountered side effects, such as
nausea, vomiting, and diarrhea were not seen. Another main
advantage of misoprostol was the cost issue. Dinoprostone
(Prostin) costs around $9 per tablet whereas misoprostol
(Cytotec) is worth $0.20 per tablet. Prepidil and Cervidil cost
$150 and $175 per insert, respectively, whereas a 100-mg
Cytotec tablet costs $0.60 [20]. The issue of temperature
stability further enhances the performance of misoprostol while
making dinoprostone (which requires maintenance of cold
chain) a less feasible option for countries with mainly warm
climate all the year around.Conclusion
We find misoprostol to be a more effective alternative to
dinoprostone for induction of labor at term. Low cost and
temperature insensitivity are its added benefits. No drug
available in the market can be labeled as absolutely safe and
good for all. The point we are trying to make is that poverty
exists everywhere, but it is most cruel and debilitating in
developing countries, where more than one person in five
subsists on less than $1/day (World Bank ReportdWorld
Development indicators 2005). With the average rate of labor
induction at term falling between 9% and 15% of the term
pregnancies, can we not strongly recommended that interna-
tional drug regulatory bodies including FDA, allow licensed use
of misoprostol in low risk pregnancies for induction of labor at
term to help doctors achieve cost-effective optimal treatment
for their patients.
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